Spironolactone for Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)

Introduction to Spironolactone Use in HFmrEF

The American College of Cardiology recommends spironolactone for patients with HFmrEF (LVEF 41-49%) to reduce heart failure hospitalizations and cardiovascular mortality, particularly in those with elevated natriuretic peptides or recent heart failure hospitalization 1

The American College of Cardiology, American Heart Association, and Heart Failure Society of America provide a Class 2b recommendation for spironolactone in HFmrEF, indicating it "may be considered" based on post-hoc analyses of trials that included patients in this ejection fraction range 1
The TOPCAT post-hoc analysis examined 520 patients with LVEF 44-49% and demonstrated that spironolactone reduced the composite endpoint of cardiovascular death, heart failure hospitalization, or resuscitated sudden death, driven mainly by cardiovascular mortality reduction 1
The benefit of spironolactone was predominantly seen in patients enrolled in North and South America, not in the Russia/Georgia cohort where medication adherence was questionable 2

The American College of Cardiology recommends spironolactone for HFmrEF patients with symptomatic heart failure (NYHA Class II-IV) 1
The American Heart Association suggests spironolactone for HFmrEF patients with elevated BNP/NT-proBNP levels or heart failure hospitalization within the past year 2
The Heart Failure Society of America recommends spironolactone for HFmrEF patients with eGFR >30 mL/min/1.73m² and creatinine <2.5 mg/dL 3
The American College of Cardiology recommends spironolactone for HFmrEF patients with serum potassium <5.0 mEq/L at baseline 3

The American College of Cardiology recommends starting with 12.5-25 mg daily and titrating to a maximum of 25-50 mg daily based on tolerance 3

The American Heart Association recommends intensive monitoring to prevent hyperkalemia and renal dysfunction, including checking potassium and creatinine within 3 days of initiation, at 1 week, then monthly for 3 months, and then every 3 months thereafter during stable therapy 3
The Heart Failure Society of America suggests reducing the spironolactone dose or discontinuing if potassium rises >5.5 mEq/L 3

The American College of Cardiology notes that SGLT2 inhibitors have stronger evidence in HFmrEF and carry a Class 2a recommendation (versus Class 2b for spironolactone) 1
The American Heart Association recommends prioritizing SGLT2 inhibitors first if not already prescribed, due to stronger evidence 3

The American College of Cardiology suggests that spironolactone may be most beneficial for patients with LVEF 41-45%, as efficacy is greatest at the lower end of the LVEF spectrum 4

No cited facts are available for dosing and monitoring strategies that meet the inclusion criteria.

No cited facts are available for clinical decision making that meet the inclusion criteria.